The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer-Reference-Cited by-同舟云学术

The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer

Published:2015-04 Issue:4 Volume:193 Page:1163-1169
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Loeb Stacy¹,Sanda Martin G.²,Broyles Dennis L.³,Shin Sanghyuk S.³,Bangma Chris H.⁴,Wei John T.⁵,Partin Alan W.⁶,Klee George G.⁷,Slawin Kevin M.⁸,Marks Leonard S.⁹,van Schaik Ron H.N.¹⁰,Chan Daniel W.¹¹,Sokoll Lori J.¹¹,Cruz Amabelle B.³,Mizrahi Isaac A.³,Catalona William J.¹²

Affiliation:

1. Department of Urology and Population Health, New York University, New York, New York

2. Department of Urology, Emory University and Emory Healthcare, Atlanta, Georgia

3. Beckman Coulter Incorporated, Carlsbad, California

4. Department of Urology, Erasmus University Medical Center, Rotterdam, the Netherlands

5. Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan

6. Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland

7. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota

8. Vanguard Urologic Institute and Texas Prostate Center, Houston, Texas

9. Department of Urology, University of California Los Angeles, Los Angeles, California

10. Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands

11. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland

12. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference24 articles.

1. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement;Moyer;Ann Intern Med,2012

2. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up;Schroder;Lancet,2014

3. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up;Andriole;J Natl Cancer Inst,2012

4. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer;Christensson;J Urol,1993

5. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study;Lazzeri;Eur Urol,2013

Cited by 221 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Biofluid Assays for Prostate Cancer;Cancers;2023-12-28

2. Applications of nanofibers drug delivery system in cancer therapy;Journal of Drug Delivery Science and Technology;2023-12

3. Development and validation of a novel nomogram predicting clinically significant prostate cancer in biopsy‐naive men based on multi‐institutional analysis;Cancer Medicine;2023-11-28

4. Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer;Urologic Oncology: Seminars and Original Investigations;2023-11

5. Role of psa levels and pathological stadiation before radiation therapy in predicting mp-MRI results in patients with prostate cancer recurrence after radical prostatectomy;Actas Urológicas Españolas (English Edition);2023-11